Q2 2025 Management View Kabir Kumar Nath, CEO, announced the appointment of Justin Gover, former CEO of GW Pharmaceuticals, to the Board of Directors, highlighting his experience with "Epidiolex, the ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, COMPASS ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today ...

Last Friday, U.K.-based Compass Pathways (NASDAQ: CMPS) became the first psychedelic medicine company to go public on a major U.S. exchange. The drugmaker's shares promptly rose by an eye-catching ...

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who ...

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...

The 3Q24 update from Compass Pathways surprised the market with news that timelines for the group’s COMP360 Phase 3 trials had been extended. The company is reducing staff headcount by ~30% and ...

LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its ...

Business Insider spoke with Compass Pathways CEO George Goldsmith in one of the company's first interviews since its IPO. Compass Pathways went public on the Nasdaq in September, and its stock popped ...

Compass Pathways is set to start its biggest clinical trial yet by the end of this year. It will study whether synthetic psilocybin can help people with treatment-resistant depression. Compass' new ...

Analysts are expecting Compass Pathways' stock to blast off soon. There aren't actually any expected near-term events which might drive such a rise. It's fully believable that the company will become ...

Compass Pathways has seen its shares slide in a big way this year. The drugmaker, however, has made significant progress on the clinical front in 2021. This clinical-stage biopharma could be a big ...